Welcome back, Pharma & Life Sciences colleagues.
In our last edition, we explored AI as a force multiplier in pharmacovigilance—not a replacement for human intelligence. This time, we're going deeper, grounding that conversation in the real-world situations many of us have witnessed or lived through.
Human review in PV is not a procedural checkbox. It is the ethical and clinical bedrock of drug safety.
1. AI Sees Patterns. Humans See Context.
AI excels at scale—processing thousands of adverse event reports overnight. But scale without context can be dangerously misleading.
The "Headache" That Wasn't
An AI system flagged a cluster of "severe headache" reports linked to a newly launched migraine drug. Automated causality scoring tagged it as a probable adverse reaction. But a human reviewer recognized what the algorithm couldn't: these patients were experiencing breakthrough migraine symptoms—not a drug-induced event. The context changed everything.
2. Statistical Correlation Is Not Clinical Judgment
Consider this example from a mid-sized pharma company:
The Elderly Patient "Fall" Signal
An AI system scanning EHR data detected a spike in falls and fractures among elderly patients on a widely prescribed antihypertensive. Statistically, the signal was robust. But clinical review revealed that the falls were linked to underlying frailty and polypharmacy—not the drug itself. The numbers pointed one way; human judgment pointed another.
3. Novel Risks Demand Human Interpretation
The COVID-19 vaccine rollout pushed global PV systems to their limits. AI helped manage volume—but not uncertainty.
The Rare Blood Clot Cases
Early reports of CVST following vaccination didn't match any historical patterns. AI models trained on pre-pandemic data had no reference frame. It took human vigilance—connecting disparate clinical clues across continents—to recognize a new safety signal. Algorithms flagged outliers; clinicians identified a syndrome.
4. Language and Culture Still Matter
Global pharmacovigilance isn't just multilingual—it's deeply cultural.
"My Heart Feels Heavy"
Social media monitoring tools flagged posts describing a "heavy heart" in patients taking an antidepressant and automatically categorized them as potential cardiac events. But human reviewers understood the cultural idiom: emotional distress, not cardiovascular pathology. Machine translation missed what human empathy caught.
5. Accountability Cannot Be Automated
Perhaps the most critical question isn't what AI can do but who remains accountable.
he Missed Anaphylaxis Case
An AI-based prioritization model deprioritized a fatal allergic reaction because the reporter used lay language ("throat closed up") instead of clinical terminology ("laryngeal edema"). The algorithm triaged it as low priority. The human reviewer, fortunately, caught it in time. But the lesson is stark: responsibility rests with people, not probabilities.
Building PV Systems That Are Actually Safer
These are not edge cases. They are everyday realities for pharmacovigilance teams worldwide.
AI is a powerful assistant it can triage, cluster, and prioritize. But humans remain the decision-makers: we assess context, apply judgment, and bear responsibility.
Practical, experience-based principles:
- Every AI-generated signal must be validated by a qualified reviewer.
- Train models on diverse data—but never assume they understand human nuance.
- Require documented justification when experts override AI outputs.
- Encourage regular cross-functional reviews involving clinicians, data scientists, and PV professionals.---
Let’s Discuss
Have you seen situations where human expertise corrected an AI-driven conclusion? Or where AI meaningfully reduced noise and allowed your team to focus on higher-value analysis?
Share your experiences—practical insight from the field is how we build better PV systems.
Remember: In pharmacovigilance, we are not processing reports. We are protecting people. Technology should support human judgment, not replace responsibility.
Follow this newsletter for practical insights at the intersection of healthcare and technology.
Subscribe to stay informed on building pharmacovigilance systems that are smarter, safer, and truly human-centric.
Because in the age of artificial intelligence, human wisdom must remain at the center of drug safety.
Leave a Comment